AHA In Brief
Medtronic PACE trial: Patients who received biventricular pacing with Medtronic's InSync III cardiac resynchronization therapy pacemaker (CRT-P) had no change in ejection fraction after one year, compared to a 6.8% reduction in ejection fraction for patients receiving right ventricular pacing alone, according to results of the Pacing to Avoid Cardiac Enlargement (PACE) trial presented Nov. 15 at the American Heart Association Scientific Sessions in Orlando. The data, which include 177 patients, were published online the same day in the New England Journal of Medicine. In addition, patients in the biventricular pacing group had no change in left ventricular size, while the right ventricular pacing arm saw a significant increase of 6.3 mL on average. Medtronic is also conducting the randomized, double-blind BLOCK-HF trial comparing biventricular and right ventricular pacing in heart failure patients with atrioventricular block; data on primary outcome measures are expected in late 2012. Biventricular pacing is currently not approved for pacemaker patients with normal pumping hearts, Medtronic notes
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.
The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.